FDA Puts All Hands on Deck to Review Pfizer-BioNTech Covid Shot

U.S. drug regulators are taking an “all-hands-on-deck approach” to reviewing Pfizer Inc. and BioNTech SE’s Covid-19 shot for full approval in an effort to persuade as many as possible to get immunized.

The Food and Drug Adminstration is “identifying additional resources such as personnel and technological resources from across the agency and opportunities to reprioritize other activities, in order to complete our review to help combat this pandemic surge,” agency spokesperson Abby Capobianco said. Acting Director Janet Woodcock has “offered all agency resources to the team to make this happen,” she said.